• Pulmotect Completes Second Clinical Trial, Closes $1.75M Investment, Earns $1M NIH Award
• Pulmotect Awarded $3 Million NIH Grant to Fund Infection Prevention Drug Trials
• Pulmotect Completes Clinical Testing, Receives CPRIT Funding for Continued Development
• Pulmotect Wins Southeast BIO Early Stage Shootout
• CPRIT Awards Pulmotect $7.1 Million to Develop Novel Immune Stimulant
• Texas Emerging Technology Fund Makes Investment in Pulmotect
• Lab Finds Fast Way to Boost Immunity
• Breathe Deep Against Bacteria
• Germ-Fighting Inhaler Could Fend Off Bioterror Agents
• Aerosol Launches Immune Response in Lungs to Wipe Out Lethal Infections
• Nasal Spray Protects Against Deadly Lung Infections
• Aerosol Immune Builder May Prevent Pneumococcal Pneumonia in Cancer Patients
• Aerosol Therapy May Offer Hope to Infection-Prone Patients
• In Our Labs: Wiping Out Lethal Infections
• Tour of Texas: Surge Ventures, Dell, Fannin Innovation, CellRight
  Xconomy - April 2016
• Pulmotect Completes Second Clinical Trial, Obtains Funding
  Pharmacy Choice - April 2016
• Synthetic inhaled drug prevents pneumonia in cancer patients
  Scrip Pharma Intelligence - December 2015
• Texas Roundup: Pulmotect, Tech Wildcatters, Houston2035, & SynShark
  Xconomy - June 2015
• Preventing airborne infection: Pulmotect arms the lungs with extra immunity
  Med City News - Jun 1, 2015
• Houston biotech company receives $3 million
  Houston Business Journal - May 2015